- Home
- MXE vs RNXT Comparison
MXE vs RNXT Comparison
Compare MXE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MXE | RNXT |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 36.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MXE | RNXT |
|---|---|---|
| Price | $12.39 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 5.8K | ★ 295.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.40 | $0.70 |
| 52 Week High | $11.51 | $1.69 |
Technical Indicators
Market Signals| Indicator | MXE | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 74.64 | 51.82 |
| Support Level | $11.96 | $0.92 |
| Resistance Level | $12.45 | $0.93 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 92.87 | 81.94 |
Price Performance
Historical ComparisonAbout MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.